A prospective randomized evaluation of the prophylactic use of low-dose dopamine in cancer patients receiving interleukin-2

被引:14
作者
Cormier, JN [1 ]
Hurst, R [1 ]
Vasselli, J [1 ]
Lee, D [1 ]
Kim, CJ [1 ]
McKee, M [1 ]
Venzon, D [1 ]
White, D [1 ]
Marincola, FM [1 ]
Rosenberg, SA [1 ]
机构
[1] NCI,SURG BRANCH,NIH,BETHESDA,MD 20892
来源
JOURNAL OF IMMUNOTHERAPY | 1997年 / 20卷 / 04期
关键词
dopamine; interleukin-2; renal dysfunction; melanoma; renal cell cancer;
D O I
10.1097/00002371-199707000-00006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The administration of high-dose interleukin-2 (IL-2) causes tumor regression in 17-25% of patients with metastatic melanoma or renal cell carcinoma. Renal dysfunction is a common dose-limiting toxicity of IL-2 administration, limiting 26% of treatment cycles. We have conducted a prospective randomized trial to evaluate whether the prophylactic administration of low-dose dopamine (2 mg/kg/min) can minimize renal toxicity and thus affect the amount of IL-2 administered. Forty-two patients were randomly assigned to receive systemic high-dose IL-2 with standard supportive measures (group A = 21 patients) or with the addition of prophylactic dopamine (group B = 21 patients) at 2 mg/kg/min. For patients in group B, dopamine was instituted 1 h before the initiation of IL-2 administration and was discontinued 6-12 h after the maximum number of doses of IL-2 were given. There was no difference in the amount of IL-2 administered for each course of therapy for groups A and B, Despite differences in urine Bow (milliliters per kilogram per day), fluid balance (liters per day), and overall weight gain, prophylactic low-dose dopamine did not significantly alter maximum plasma urea or creatinine levels in group B when compared with the control group (group A). Tnt overall toxicity profile considering all grade 3 and 4 toxicities for patients in groups A and B was comparable. Thus, there is no evidence to support the routine use of prophylactic low-dose dopamine in patients receiving high-dose IL-2.
引用
收藏
页码:292 / 300
页数:9
相关论文
共 31 条
[1]   EFFECT OF POSTOPERATIVE LOW-DOSE DOPAMINE ON RENAL FUNCTION AFTER ELECTIVE MAJOR VASCULAR-SURGERY [J].
BALDWIN, L ;
HENDERSON, A ;
HICKMAN, P .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (09) :744-747
[2]   RENAL TOXICITY OF INTERLEUKIN-2 ADMINISTRATION IN PATIENTS WITH METASTATIC RENAL-CELL CANCER - EFFECT OF PRE-THERAPY NEPHRECTOMY [J].
BELLDEGRUN, A ;
WEBB, DE ;
AUSTIN, HA ;
STEINBERG, SM ;
LINEHAN, WM ;
ROSENBERG, SA .
JOURNAL OF UROLOGY, 1989, 141 (03) :499-503
[3]   EFFECTS OF INTERLEUKIN-2 ON RENAL-FUNCTION IN PATIENTS RECEIVING IMMUNOTHERAPY FOR ADVANCED CANCER [J].
BELLDEGRUN, A ;
WEBB, DE ;
AUSTIN, HA ;
STEINBERG, SM ;
WHITE, DE ;
LINEHAN, WM ;
ROSENBERG, SA .
ANNALS OF INTERNAL MEDICINE, 1987, 106 (06) :817-822
[4]   CLEARANCE RATES AND SYSTEMIC EFFECTS OF INTRAVENOUSLY ADMINISTERED INTERLEUKIN-2 (IL-2) CONTAINING PREPARATIONS IN HUMAN-SUBJECTS [J].
BINDON, C ;
CZERNIECKI, M ;
RUELL, P ;
EDWARDS, A ;
MCCARTHY, WH ;
HARRIS, R ;
HERSEY, P .
BRITISH JOURNAL OF CANCER, 1983, 47 (01) :123-133
[5]   NEPHROTOXICITY OF CONTINUOUS INTRAVENOUS-INFUSION OF RECOMBINANT INTERLEUKIN-2 [J].
CHRISTIANSEN, NP ;
SKUBITZ, KM ;
NATH, K ;
OCHOA, A ;
KENNEDY, BJ .
AMERICAN JOURNAL OF MEDICINE, 1988, 84 (06) :1072-1075
[6]   ACUTE CYCLOSPORINE RENAL DYSFUNCTION REVERSED BY DOPAMINE INFUSION IN HEALTHY-SUBJECTS [J].
CONTE, G ;
DALCANTON, A ;
SABBATINI, M ;
NAPODANO, P ;
DENICOLA, L ;
GIGLIOTTI, G ;
FUIANO, G ;
TESTA, A ;
ESPOSITO, C ;
RUSSO, D ;
ANDREUCCI, VE .
KIDNEY INTERNATIONAL, 1989, 36 (06) :1086-1092
[7]   DOPAMINE AND RENAL SALVAGE IN THE CRITICALLY ILL PATIENT [J].
DUKE, GJ ;
BERSTEN, AD .
ANAESTHESIA AND INTENSIVE CARE, 1992, 20 (03) :277-287
[8]  
ETTINGHAUSEN SE, 1986, CANCER RES, V46, P2784
[9]  
JOSE PA, 1992, J AM SOC NEPHROL, V2, P1265
[10]   EFFECTS OF INTERLEUKIN-2 IMMUNOTHERAPY ON RENAL-FUNCTION [J].
KOZENY, GA ;
NICOLAS, JD ;
CREEKMORE, S ;
STICKLIN, L ;
HANO, JE ;
FISHER, RI .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1170-1176